Related Articles
Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours
Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.
Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin
HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.